Literature DB >> 24687033

Prostate cancer: a new look at prostate cancer treatment complications.

Matthew R Cooperberg1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24687033     DOI： 10.1038/nrclinonc.2014.58

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  The urology work force in Ontario for the 21st century: feast or famine?

Authors:  K T Pace; J L Provan; M A Jewett
Journal:  Can J Surg       Date:  1999-06       Impact factor: 2.089

Review 2.  Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy.

Authors:  Ashutosh Tewari; Prasanna Sooriakumaran; Daniel A Bloch; Usha Seshadri-Kreaden; April E Hebert; Peter Wiklund
Journal:  Eur Urol       Date:  2012-02-24       Impact factor: 20.096

3.  Outcomes for radical prostatectomy: is it the singer, the song, or both?

Authors:  Matthew R Cooperberg; Anobel Y Odisho; Peter R Carroll
Journal:  J Clin Oncol       Date:  2012-01-03       Impact factor: 44.544

4.  Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study.

Authors:  Robert K Nam; Patrick Cheung; Sender Herschorn; Refik Saskin; Jiandong Su; Laurence H Klotz; Michelle Chang; Girish S Kulkarni; Yuna Lee; Ronald T Kodama; Steven A Narod
Journal:  Lancet Oncol       Date:  2014-01-17       Impact factor: 41.316

5.  Variations in morbidity after radical prostatectomy.

Authors:  Colin B Begg; Elyn R Riedel; Peter B Bach; Michael W Kattan; Deborah Schrag; Joan L Warren; Peter T Scardino
Journal:  N Engl J Med       Date:  2002-04-11       Impact factor: 91.245

6.  Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.

Authors:  Matthew R Cooperberg; Andrew J Vickers; Jeanette M Broering; Peter R Carroll
Journal:  Cancer       Date:  2010-11-15       Impact factor: 6.860

7.  National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer.

Authors:  Patricia A Ganz; John M Barry; Wylie Burke; Nananda F Col; Phaedra S Corso; Everett Dodson; M Elizabeth Hammond; Barry A Kogan; Charles F Lynch; Lee Newcomer; Eric J Seifter; Janet A Tooze; Kasisomayajula Viswanath; Hunter Wessells
Journal:  Ann Intern Med       Date:  2012-02-20       Impact factor: 25.391

8.  Low annual caseloads of United States surgeons conducting radical prostatectomy.

Authors:  Caroline J Savage; Andrew J Vickers
Journal:  J Urol       Date:  2009-12       Impact factor: 7.450

9.  Differing perceptions of quality of life in patients with prostate cancer and their doctors.

Authors:  Geoffrey A Sonn; Natalia Sadetsky; Joseph C Presti; Mark S Litwin
Journal:  J Urol       Date:  2009-09-16       Impact factor: 7.450

10.  Provider case volume and outcomes following prostate brachytherapy.

Authors:  Aileen B Chen; Anthony V D'Amico; Bridget A Neville; Ewout W Steyerberg; Craig C Earle
Journal:  J Urol       Date:  2008-11-13       Impact factor: 7.450
  10 in total
  5 in total

1.  ANTITUMOR EFFECTS OF CHRYSANTHEMIN IN PC-3 HUMAN PROSTATE CANCER CELLS ARE MEDIATED VIA APOPTOSIS INDUCTION, CASPASE SIGNALLING PATHWAY AND LOSS OF MITOCHONDRIAL MEMBRANE POTENTIAL.

Authors:  De-Kang Sun; Lin Wang; Peng Zhang
Journal:  Afr J Tradit Complement Altern Med       Date:  2017-06-05

2.  LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling.

Authors:  Jie Luo; Keliang Wang; Shuyuan Yeh; Yin Sun; Liang Liang; Yao Xiao; Wanhai Xu; Yuanjie Niu; Liang Cheng; Sankar N Maity; Runze Jiang; Chawnshang Chang
Journal:  Nat Commun       Date:  2019-06-12       Impact factor: 14.919

3.  E2F transcription factor 2-activated DLEU2 contributes to prostate tumorigenesis by upregulating serum and glucocorticoid-induced protein kinase 1.

Authors:  Peizhang Li; Huan Xu; Liu Yang; Ming Zhan; Yuanping Shi; Caoxu Zhang; Dajun Gao; Meng Gu; Yanbo Chen; Zhong Wang
Journal:  Cell Death Dis       Date:  2022-01-24       Impact factor: 8.469

4.  MAFG-AS1 is a prognostic biomarker and facilitates prostate cancer progression.

Authors:  Peizhang Li; Yuanping Shi; Miaomiao Guo; Huan Xu; Ming Zhan; Zhong Wang; Yanbo Chen
Journal:  Front Oncol       Date:  2022-08-05       Impact factor: 5.738

5.  The role of the histone H3 variant CENPA in prostate cancer.

Authors:  Anjan K Saha; Rafael Contreras-Galindo; Yashar S Niknafs; Matthew Iyer; Tingting Qin; Karthik Padmanabhan; Javed Siddiqui; Monica Palande; Claire Wang; Brian Qian; Elizabeth Ward; Tara Tang; Scott A Tomlins; Scott D Gitlin; Maureen A Sartor; Gilbert S Omenn; Arul M Chinnaiyan; David M Markovitz
Journal:  J Biol Chem       Date:  2020-05-05       Impact factor: 5.157
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.